It seems like ages–in reality, only two years or so [TTA 19 Dec 15]–that this Editor was writing hopefully about advances in exoskeletons such as ReWalk and Wyss, EKSO plus DARPA research in assisting the mobility of paraplegics and others who need assistance in major movement. And then the news went rather dark, though ReWalk is now in its sixth iteration.
So it is heartening to be able to report that an established healthcare robotics company, Toronto’s Bionik Laboratories, is investing in a joint venture with Boston-based Wistron Corporation, an industrial design and manufacturing company, to further develop the Bionik ARKE lower body exoskeleton. Bionik’s emphasis has been on rehabilitative hospital-to-home upper body robotics to assist patients with regaining mobility. The ARKE appears to be both rehabilitative and assistive for patients in the home. Once developed in the JV, Wistron would be the sole manufacturer.
According to Crunchbase, Bionik raised $13.1 million in a July 2015 private placement specifically to develop the ARKE (MassDevice). This past May, they raised about $2 million from Hong Kong’s Ginger Capital in a separate JV to sell their robotics into the Chinese market. Bionik partnered with IBM starting last year to develop machine learning to analyze the data generated by the ARKE (FierceBiotech).
The target market for the Bionik/Wistron JV is not in this context a surprise. It is the booming older adult Asian market, where the aging/elderly population is projected to hit 983 million by 2050. Many especially in China and India live in rural areas and aren’t covered by any pension or old-age support (ADB Research). It is not clear to this Editor how expensive lower-body exoskeletons will be supported financially either privately or by government. Bionik release, FierceBiotech